4-(2,6-dimethyl-phenylamino)-6-methylcarbamoyl-quinoline-3-carboxylic acid | 1256468-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(2,6-dimethyl-phenylamino)-6-methylcarbamoyl-quinoline-3-carboxylic acid
• 英文别名: 4-(2,6-Dimethylanilino)-6-(methylcarbamoyl)quinoline-3-carboxylic acid
• CAS: 1256468-37-7
• 化学式: C₂₀H₁₉N₃O₃
• 分子量: 349.389
• InChiKey: GAQGCIDHXZCPHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  91.3
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(2,6-dimethyl-phenylamino)-6-methyl-carbamoyl-quinoline-3-carboxylic acid ethyl ester 在 lithium hydroxide monohydrate 、 水 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 以57%的产率得到4-(2,6-dimethyl-phenylamino)-6-methylcarbamoyl-quinoline-3-carboxylic acid
  参考文献：
  名称：

  [EN] DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE
  [FR] DÉRIVÉS D'ACIDE QUINOLÉINE-3-CARBOXYLIQUE ET LEUR UTILISATION MÉDICALE

  摘要：

  翻译结果为：具有公式(I)的化合物，以及其药用可接受的盐和包含治疗有效量的该化合物的药物组合物。这些化合物可用于治疗癌症、糖尿病性视网膜病变、年龄相关性黄斑变性、炎症、中风、缺血性心肌、动脉硬化、黄斑水肿或银屑病。

  公开号：

  WO2010133672A1

文献信息

• Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases
  申请人：Clanotech AB

  公开号：US20150031723A1

  公开（公告）日：2015-01-29

  A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.
• US9376393B2
  申请人：——

  公开号：US9376393B2

  公开（公告）日：2016-06-28
• [EN] QUINOLINE COMPOUNDS WHICH ARE ANTI-ANGIOGENIC INTEGRIN ALPHA5 BETAL INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS OR FIBROSIS-RELATED DISEASES<br/>[FR] COMPOSÉS QUINOLÉINE UTILISÉS COMME INHIBITEURS DE L'INTÉGRINE ALPHA5 BÊTA1 ANTI-ANGIOGÉNIQUES POUR TRAITER UNE FIBROSE OU DES MALADIES LIÉES À UNE FIBROSE
  申请人：CLANOTECH AB

  公开号：WO2013103317A1

  公开（公告）日：2013-07-11

  A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.
• [EN] DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE<br/>[FR] DÉRIVÉS D'ACIDE QUINOLÉINE-3-CARBOXYLIQUE ET LEUR UTILISATION MÉDICALE
  申请人：CLANOTECH AB

  公开号：WO2010133672A1

  公开（公告）日：2010-11-25

  A compound of formula (I) as well as pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising a therapeutically effective amount of the compounds. The compounds are useful in treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema or psoriasis.

  翻译结果为：具有公式(I)的化合物，以及其药用可接受的盐和包含治疗有效量的该化合物的药物组合物。这些化合物可用于治疗癌症、糖尿病性视网膜病变、年龄相关性黄斑变性、炎症、中风、缺血性心肌、动脉硬化、黄斑水肿或银屑病。